Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

IFNA2 antibody (Biotin)

This anti-IFNA2 antibody is a Mouse Monoclonal antibody detecting IFNA2 in ELISA and ELISpot. Suitable for Human. This Primary Antibody has been cited in 5+ publications.
Catalog No. ABIN6963844

Quick Overview for IFNA2 antibody (Biotin) (ABIN6963844)

Target

See all IFNA2 Antibodies
IFNA2 (Interferon, alpha 2 (IFNA2))

Reactivity

  • 82
  • 3
  • 2
  • 1
Human

Host

  • 51
  • 34
  • 3
Mouse

Clonality

  • 50
  • 34
  • 2
Monoclonal

Conjugate

  • 37
  • 10
  • 4
  • 3
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
This IFNA2 antibody is conjugated to Biotin

Application

  • 45
  • 31
  • 19
  • 16
  • 16
  • 13
  • 9
  • 9
  • 9
  • 7
  • 4
  • 3
  • 3
  • 2
  • 2
  • 1
  • 1
  • 1
  • 1
  • 1
  • 1
ELISA, ELISpot

Clone

MT2
  • Specificity

    Native and recombinant human IFN-α subtypes 2a, 2b, 2c

    Purification

    Biotinylated through reaction with a N-hydroxysuccinimide ester of biotin.,Purified from in vitro cultures by protein G affinity chromatography.

    Sterility

    0.2 μm filtered

    Immunogen

    Recombinant human IFN-alpha 2c

    Isotype

    IgG1
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Liquid

    Concentration

    1 mg/mL

    Buffer

    supplied at 1 mg/mL in PBS with 0.02 % sodium azide

    Preservative

    Sodium azide

    Precaution of Use

    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

    Storage

    4 °C,-20 °C

    Storage Comment

    Store product at 4-8°C or frozen at -20°C or below. Avoid repeated freezing/ thawing.

    Expiry Date

    18 months
  • Yadav, McLeod, Nowell, Selby, Johnston, Kaminskas, Trevaskis: "Distribution of therapeutic proteins into thoracic lymph after intravenous administration is protein size-dependent and primarily occurs within the liver and mesentery." in: Journal of controlled release : official journal of the Controlled Release Society, Vol. 272, pp. 17-28, (2019) (PubMed).

    Hochmann, Mittermeir, Santic, Koszik, Griessner, Sonderegger, Hoffmann, Russe, Scheiblhofer, Weiss, Mandler, Schneeberger, Strunk: "Evaluation of modified Interferon alpha mRNA constructs for the treatment of non-melanoma skin cancer." in: Scientific reports, Vol. 8, Issue 1, pp. 12954, (2019) (PubMed).

    Chan, Feeney, Leong, McLeod, Porter, Williams, Kaminskas: "An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration." in: Biomacromolecules, Vol. 18, Issue 9, pp. 2866-2875, (2018) (PubMed).

    Bijak, Dziedzic, Synowiec, Sliwinski, Saluk-Bijak: "Flavonolignans Inhibit IL1-β-Induced Cross-Talk between Blood Platelets and Leukocytes." in: Nutrients, Vol. 9, Issue 9, (2018) (PubMed).

    Ingelsson, Söderberg, Strid, Söderberg, Bergh, Loitto, Lotfi, Segelmark, Spyrou, Rosén: "Lymphocytes eject interferogenic mitochondrial DNA webs in response to CpG and non-CpG oligodeoxynucleotides of class C." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 115, Issue 3, pp. E478-E487, (2018) (PubMed).

  • Target

    IFNA2 (Interferon, alpha 2 (IFNA2))

    Alternative Name

    IFNA2

    Gene ID

    3440

    Pathways

    JAK-STAT Signaling, Regulation of Leukocyte Mediated Immunity, Production of Molecular Mediator of Immune Response, Hepatitis C
You are here:
Chat with us!